Macular fibrosis is an end-stage complication of neovascular Age-related Macular Degeneration (nAMD) with a complex and multifactorial pathophysiology that can lead to significant visual impairment. Despite the success of anti-vascular endothelium growth factors (anti-VEGF) over the last decade that revolutionised the management and visual prognosis of nAMD, macular fibrosis develops in a significant proportion of patients and, along with macular atrophy (MA), is a main driver of long-term vision deterioration. There remains an unmet need to better understand macular fibrosis and develop anti-fibrotic therapies. The use of imaging biomarkers in combination with novel Artificial Intelligence (AI) algorithms holds significant potential for improving the accuracy of diagnosis, disease monitoring, and therapeutic discovery for macular fibrosis. In this review, we aim to provide a comprehensive overview of the current state of knowledge regarding the various imaging modalities and biomarkers for macular fibrosis alongside outlining potential avenues for AI applications. We discuss manifestations of macular fibrosis and its precursors with diagnostic and prognostic significance on various imaging modalities, including Optical Coherence Tomography (OCT), Colour Fundus Photography (CFP), Fluorescein Angiography (FA), OCT-Angiography (OCTA) and collate data from prospective and retrospective research on known biomarkers. The predominant role of OCT for biomarker identification is highlighted. The review coincides with a resurgence of intense research interest in academia and industry for therapeutic discovery and clinical testing of anti-fibrotic molecules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00417-025-06790-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Imaging biomarkers and artificial intelligence for diagnosis, prediction, and therapy of macular fibrosis in age-related macular degeneration: Narrative review and future directions.
Graefes Arch Clin Exp Ophthalmol
March 2025
Institute of Ophthalmology, University College London, London, England.
Macular fibrosis is an end-stage complication of neovascular Age-related Macular Degeneration (nAMD) with a complex and multifactorial pathophysiology that can lead to significant visual impairment. Despite the success of anti-vascular endothelium growth factors (anti-VEGF) over the last decade that revolutionised the management and visual prognosis of nAMD, macular fibrosis develops in a significant proportion of patients and, along with macular atrophy (MA), is a main driver of long-term vision deterioration. There remains an unmet need to better understand macular fibrosis and develop anti-fibrotic therapies.
View Article and Find Full Text PDFTargeting macrophage to myofibroblast transition by circ_0001103 for subretinal fibrosis treatment.
J Transl Med
February 2025
Department of Ophthalmology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241001, Anhui, People's Republic of China.
Purpose: Subretinal fibrosis is an important cause of visual loss in age-related macular degeneration, but its mechanism remains unclear. This study aims to investigate the role of macrophage-to-myofibroblast transition (MMT) in the formation of subretinal fibrosis and assess whether circ_0001103 can regulate the formation of subretinal fibrosis by regulating MMT.
Methods: Subretinal fibrosis was induced in C57BL/6J mice by laser induction.
Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i.
J Diabetes Complications
February 2025
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China; Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan 030032, China; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address:
Background: Currently, the prevalence of diabetes is rising. Patients with diabetes often face high risks of kidney disease, cardiovascular disease, and retinal disease. Cardiovascular complications are the primary cause of morbidity and mortality in patients with type 2 diabetes mellitus.
View Article and Find Full Text PDFFactors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7.
Eye (Lond)
February 2025
National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Purpose: To identify demographic and baseline OCT characteristics that are predictive of VA outcomes after the first and post-loading injections in patients treated with 2 mg aflibercept.
Methods: This study evaluated VA outcomes in 1999 eyes of 1862 patients with nAMD initiated on aflibercept therapy. Demographic and OCT (Spectralis, Heidelberg Engineering) features associated with good VA outcome defined as VA ≥ 68 ETDRS letters (Snellen ≥ 6/12) and poor VA outcome of <54 ETDRS letters (Snellen < 6/18) or a loss of ≥5 ETDRS letters after first and post-loading injections were analysed using logistic regression via generalised estimating equations.
Clinical characteristics and management outcomes of pediatric patients with Coats disease complicated with retinoschisis (retinal cyst).
Front Med (Lausanne)
February 2025
Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Purpose: To present the clinical characteristics and management outcomes of Coats disease with retinoschisis (retinal cyst).
Methods: This was a retrospective review of 13 eyes from 13 consecutive Coats disease patients with retinal cyst. Clinical findings from multimodal ophthalmic imaging were recorded to characterize retinal cyst in Coats disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!